ATZUMI Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Atzumi, and when can generic versions of Atzumi launch?
Atzumi is a drug marketed by Satsuma Pharms and is included in one NDA. There are seven patents protecting this drug.
The generic ingredient in ATZUMI is dihydroergotamine mesylate. There is one drug master file entry for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the dihydroergotamine mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Atzumi
A generic version of ATZUMI was approved as dihydroergotamine mesylate by HIKMA on June 9th, 2003.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ATZUMI?
- What are the global sales for ATZUMI?
- What is Average Wholesale Price for ATZUMI?
Summary for ATZUMI
| US Patents: | 7 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Applications: | 1,591 |
| What excipients (inactive ingredients) are in ATZUMI? | ATZUMI excipients list |
| DailyMed Link: | ATZUMI at DailyMed |
Pharmacology for ATZUMI
| Drug Class | Ergotamine Derivative |
US Patents and Regulatory Information for ATZUMI
ATZUMI is protected by seven US patents and one FDA Regulatory Exclusivity.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Satsuma Pharms | ATZUMI | dihydroergotamine mesylate | POWDER;NASAL | 217901-001 | Apr 30, 2025 | RX | Yes | Yes | 11,872,314 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Satsuma Pharms | ATZUMI | dihydroergotamine mesylate | POWDER;NASAL | 217901-001 | Apr 30, 2025 | RX | Yes | Yes | 11,744,967 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Satsuma Pharms | ATZUMI | dihydroergotamine mesylate | POWDER;NASAL | 217901-001 | Apr 30, 2025 | RX | Yes | Yes | 12,594,273 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Satsuma Pharms | ATZUMI | dihydroergotamine mesylate | POWDER;NASAL | 217901-001 | Apr 30, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ATZUMI
See the table below for patents covering ATZUMI around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 3122396 | COMPOSITIONS, DISPOSITIFS ET PROCEDES DE TRAITEMENT OU DE PREVENTION DES MAUX DE TETE (COMPOSITIONS, DEVICES, AND METHODS FOR TREATING OR PREVENTING HEADACHES) | ⤷ Start Trial |
| China | 113423400 | 用于治疗或预防头痛的组合物、装置和方法 (COMPOSITIONS, DEVICES, AND METHODS FOR TREATING OR PREVENTING HEADACHES) | ⤷ Start Trial |
| China | 120284965 | 用于治疗或预防头痛的组合物、装置和方法 (Compositions, devices and methods for treating or preventing headache) | ⤷ Start Trial |
| European Patent Office | 3893877 | COMPOSITIONS, DISPOSITIFS ET PROCÉDÉS DE TRAITEMENT OU DE PRÉVENTION DES MAUX DE TÊTE (COMPOSITIONS, DEVICES, AND METHODS FOR TREATING OR PREVENTING HEADACHES) | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch